A growing number of doctors are prescribing birth control pills to women in their 40s—and not for contraception, but as a management strategy for perimenopause. The pitch sounds appealing: control the hot flashes, regulate the erratic bleeding, smooth out the mood swings. But before you reach for the pill as your perimenopause solution, there are several important things to understand about this transition, and what hormonal contraceptives actually do and what they might be hiding.
What is perimenopause?
Perimenopause is the years-long hormonal transition leading up to your final menstrual period. It typically begins in the mid-to-late 40s and can last anywhere from two to ten years. During this time, estrogen and progesterone levels fluctuate erratically rather than declining in a straight line. That’s why symptoms can be so unpredictable. Hot flashes, irregular periods, brain fog, disrupted sleep, mood changes, vaginal dryness, and changes in libido are all common during perimenopause.
Importantly, your body is still producing hormones during perimenopause. The hardship is in the inconsistency. This is a key distinction that matters when we consider what adding synthetic hormones from an oral contraceptive actually does.
Your body is still producing hormones during perimenopause. The hardship is in the inconsistency. This is a key distinction that matters when we consider what adding synthetic hormones from an oral contraceptive actually does.
What the research says: the symptom relief argument
A 2024 narrative review published in Gynecological and Reproductive Endocrinology & Metabolism (GREM) examined studies from 2000–2024 on hormonal contraception and menopausal transition. It found that combined hormonal contraceptives (CHCs) can help control abnormal uterine bleeding, reduce vasomotor symptoms (like hot flashes), and offer some protection against endometrial hyperplasia and bone loss [1]. These are real benefits for women whose perimenopausal symptoms are genuinely disruptive.
The pill works by delivering a steady dose of synthetic estrogen and progestin, which overrides your body’s own fluctuating hormone production. For women experiencing the rollercoaster of perimenopause, this can indeed smooth things out.
The masking problem
Here’s where things get complicated, and where the “easier menopause” framing starts to fall apart.
Because hormonal contraceptives suppress your natural cycle, they make it difficult to track where you are in the menopausal transition. Menopause is defined as 12 consecutive months without a menstrual period, but on the pill, you don’t have a natural menstrual period at all—you’re having a withdrawal bleed from the synthetic hormones. These two things look similar on the surface but are hormonally entirely different.
This means that if you’re taking the pill through your 40s and into your early 50s, you may reach menopause and not know it. (You may also be experiencing other health issues that could be masked or mistaken for perimenopause that deserve competent diagnosis and care—more on that, here). While on birth control, your cycle can’t serve as a guide. Your FSH levels rise significantly as you approach menopause, but this will also be masked by the pill and won’t accurately reflect your menopausal status while you’re on it. This is one of the overarching shortcomings of hormonal contraception at every stage of a woman’s reproductive life.
Why does it matter that you know when you’ve reached menopause? Because the type of hormonal support that’s appropriate shifts significantly once you are post-menopausal. Continuing on a combined hormonal contraceptive after menopause carries different and generally higher cardiovascular and thromboembolic risks than the lower-dose hormone replacement therapy (HRT) designed specifically for post-menopausal women [2].
Continuing on a combined hormonal contraceptive after menopause carries different and generally higher cardiovascular and thromboembolic risks than the lower-dose hormone replacement therapy (HRT) designed specifically for post-menopausal women.
The ovarian reserve question
One concern sometimes raised about long-term pill use is its effect on ovarian reserve, that being the quantity of remaining eggs. Research confirms that combined oral contraceptives (OCP) do suppress ovarian reserve markers, including AMH (anti-Müllerian hormone) and antral follicle count (AFC) while a woman is actively taking them. Some studies showed markers as much as 19% lower in pill users [3]. However, current evidence suggests this suppression is temporary: a 2023 study found that among women who discontinued hormonal contraceptives, ovarian reserve markers recovered, with AMH increasing significantly within a few years of stopping [3].
This is somewhat reassuring from a fertility standpoint, but it does complicate ovarian reserve testing during perimenopause, since that’s a time when understanding your egg supply might actually matter for family planning decisions. If your AMH is suppressed by the pill, you can’t get an accurate read on where you stand with your cycle.
Birth control vs. hormone replacement therapy (HRT)
This is where the rubber really meets the road: the pill and hormone replacement therapy (HRT), while frequently conflated, are not the same thing. Combined oral contraceptives contain significantly higher doses of synthetic hormones than HRT. OCP doses are designed to suppress ovulation in a young, fertile woman’s body. HRT, by contrast, uses lower doses—ideally, of bioidentical estradiol and progesterone—calibrated to relieve symptoms in a post-menopausal body without suppressing anything.
So, for women in perimenopause who need symptom relief, bioidentical HRT may actually be the better-suited option: lower doses of more physiologically-matched hormones, and without the cycle-masking effect that makes it difficult to track your transition. The 2024 GREM review acknowledges that while combined hormonal contraceptives can be appropriate for some perimenopausal women, the choice between contraception and HRT should be made carefully based on individual symptoms, health history, and reproductive goals [1]. Nonetheless, it is worth noting that HRT carries fewer downsides overall, and therefore it is likely worth considering first.
What to ask your doctor
If you’re in your 40s and considering the pill for perimenopause, there are a few questions worth raising with your healthcare professional.
- How will you determine when I’ve actually reached menopause?
- What’s the plan for transitioning from pill to a menopause-appropriate treatment if needed?
- Are there lower-hormone options (including bioidentical HRT) that might achieve the same symptom relief?
- What are my individual cardiovascular and thrombotic risk factors, and how do they interact with pill use in my age group?
The bottom line
It is true that birth control pills can reduce some perimenopausal symptoms. But they don’t make perimenopause “easier” so much as they make it invisible, overriding your body’s own signals in a way that can delay diagnosis, complicate treatment decisions, and obscure important information about your hormonal health. The menopause transition deserves to be understood, not suppressed. If you’re navigating perimenopause, the most empowering step you can take is working with a healthcare professional who will help you read what your body is actually doing, not just quiet it down (and for more information on how to do that, listen to this episode of The Natural Womanhood Podcast on Perimenopause 101: What Every Woman Needs to Know).
References
- Fidecicchi T.,Ardito M.,Giudetti M.,Luisi S.,Simoncini T., Hormonal contraception and menopausal transition: a short review, GREM Gynecological and Reproductive Endocrinology & Metabolism (2024); doi: 10.53260/grem.245026
- de Barros VIPVL, de Oliveira ALML, do Nascimento DJ, Zlotnik E, Teruchkin MM, Marques MA, Margarido PFR. Use of hormones and risk of venous thromboembolism. Rev Bras Ginecol Obstet. (2024); doi: 10.61622/rbgo/2024FPS02. PMID: 38765519; PMCID: PMC11075397.
- Siegel DR, Fresia J, Fought A, Sheeder J, Hampanda K, Appiah L. The Effect of Hormonal Contraception Use on Ovarian Reserve Markers and the Uptake of Assisted Reproductive Technology in Individuals Seeking an Infertility Evaluation. Cureus. 2023 Jun 25;15(6):e40927. doi: 10.7759/cureus.40927. PMID: 37496533; PMCID: PMC10368143.
